Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 24, 2009

Roche Earmarks €4M for Rare Disease Collaboration with Andalucian Region's DoH

  • Roche will invest €4 million ($5.98 million) into a new Medical Genome Project in collaboration with the Junta de Andalucia Department of Health. The three-year partnership, scheduled to start next year, aims to identify the genetic causes of rare diseases and develop new therapeutics that target gene-specific disorders. The overall goal will be the development of personalized therapies tailored to individuals’ genetic makeup. The project is the brainchild of the Spanish DoH, but Roche will retain the right of first refusal to license relevant discoveries. 

    Hands-on research for the project will be carried out in Seville and led by researchers at the Andalusian Genetic Plan and the Andalusian Program for Genetic Research and Genomics at Cartuja 93.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »